Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Femasys Inc (FEMY)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$1.31-9.03%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for FEMY yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain Nasdaq listing compliance and focus on growth | A supporting condition in Femasys Inc's published investment case. The stated target is Remain compliant with Nasdaq listing rules. | Recovered | Company loses Nasdaq listing compliance | Compliant vs Nasdaq rules Femasys regained Nasdaq listing compliance in June 2026 and shifted focus to growth strategy. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making commercialization story, not a proven durable compounder. The thesis is on watch: management has advanced product initiatives, but recent financial performance remains weak and earnings have been erratic.
The evidence describes FEMY as cheap versus peers, with a negative expectations gap, meaning market expectations appear cautious relative to the valuation model. The model has medium confidence, and the evidence does not give enough detail to say more about what the market assumes.
Near term, revenue progress may remain uneven: first-half 2026 sales rose modestly from 2025, with FemBloc supporting first-quarter growth but lower FemVue sales weighing on the second quarter. Losses remain substantial, and cash fell in the second quarter before a private placement strengthened liquidity; funding needs and the next guidance update remain risks.
Over the next 1 to 3 years, the thesis hinges on whether FemaSeed and FemBloc commercialization can produce more consistent growth while operating losses narrow. A guidance cut or further weakening in employment could weigh on the business outlook, while continued strength among healthcare sector leaders could support the sector backdrop.
FEMY has early signs of product execution, but weak results, ongoing losses, and cash needs keep the multi-year view uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Femasys is improving its losses, cutting operating losses by $0.4M. |
| Intact |
| Operating loss does not improve by $0.4M or worsens next quarter |
Operating income: $-5.066M FY2026-Q2; GAAP. Published target: Operating loss improves by at least $0.4M in next quarter. The target does not explicitly identify fiscal versus calendar quarters. Aug 14, 2026-5,065,874 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve revenue growth of about 15% next year | Analysts expect revenue to grow about 15% next year. | Improving | Revenue growth falls below 15% next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-5.27 → $-2.13 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-07-25 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-07-26 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-07-27 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-07-28 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-07-29 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-07-30 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-07-31 | $-5.80 | $10,002,000 | 2 / 3 |
| 2026-08-01 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-08-02 | $-5.80 | $10,002,000 | 2 / 3 |
| 2026-08-03 | $-5.80 | $10,002,000 | 2 / 3 |
| 2026-08-04 | $-5.80 | $10,002,000 | 2 / 3 |
| 2026-08-05 | $-5.80 | $10,002,000 | 2 / 3 |
| 2026-08-06 | $-5.80 | $10,002,000 | 2 / 3 |
| 2026-08-07 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-08-08 | $-5.80 | $10,002,000 | 2 / 3 |
| 2026-08-09 | $-5.80 | $10,002,000 | 2 / 3 |
| 2026-08-10 | $-5.80 | $10,002,000 | 2 / 3 |
| 2026-08-11 | $-5.80 | $10,002,000 | 2 / 3 |
| 2026-08-12 | $-5.80 | $10,002,000 | 2 / 3 |
| 2026-08-13 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-08-14 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-08-15 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-08-16 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-08-17 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-08-18 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-08-19 | $-5.27 | $10,002,000 | 2 / 3 |
| 2026-08-20 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-08-21 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-08-22 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-08-23 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-08-24 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-08-25 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-08-26 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-08-27 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-08-28 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-08-29 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-08-30 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-08-31 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-01 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-02 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-03 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-04 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-05 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-06 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-07 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-08 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-09 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-10 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-11 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-12 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-13 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-14 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-15 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-16 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-17 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-18 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-19 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-20 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-21 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-22 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-23 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-24 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-25 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-26 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-27 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-28 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-29 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-09-30 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-01 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-02 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-03 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-04 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-05 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-06 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-07 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-08 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-09 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-10 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-11 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-12 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-13 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-14 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-15 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-16 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-17 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-18 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-19 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-20 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-21 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-22 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-23 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-24 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-25 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-26 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-27 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-28 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-29 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-30 | $-1.75 | $8,935,333 | 2 / 3 |
| 2026-10-31 | $-2.13 | $9,437,500 | 2 / 3 |
| 2026-11-01 | $-2.13 | $9,437,500 | 2 / 3 |
| 2026-11-02 | $-2.13 | $9,437,500 | 2 / 3 |
| 2026-11-03 | $-2.13 | $9,437,500 | 2 / 2 |
| 2026-11-04 | $-2.13 | $9,437,500 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.